World-first clinical trial raises hopes of new drug for chronic lung disease
CHRONIC lung disease sufferers could be aided by a new drug which helps reduce the need for antibiotics, according to a clinical trial....
IGF2R Blood Levels May Help Predict Antibiotic Response in CF Pulmonary Exacerbations, Study Says
Measuring the levels of insulin-like growth factor 2 receptor (IGF2R) during the first days of treatment with intravenous antibiotics...
MAC Lung Infections Best Treated When Specific Bacterial Species Known, Study Finds
Pulmonary infection with a specific species of the Mycobacterium avium complex (MAC), called Mycobacterium intracellulare, can be...
Pregnancy in CF Women With Poor Lung Function Not Linked to Pulmonary Decline, Study Shows
Poorer lung function in pregnant women with cystic fibrosis (CF) is associated with a lower birth weight for offspring, and a higher...
SNSP113 (Previously SYGN113)
SNSP113 is an inhaled therapy being developed by Synspira Therapeutics that aims to ease pulmonary infections, airway congestion, and...
Corbus Pharma (CRBP) Reports Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmon
Multi-national Phase 2b is designed to provide clear evidence of clinical benefit of lenabasum (formerly known as anabasum) in patients...
Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
Abstract CMV is an unusual cause of pulmonary exacerbation in immunocompetent individuals with CF http://ow.ly/Rdds30hlnjV To the Editor:...
